Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association of apolipoprotein M and sphingosine-1-phosphate with brown adipose tissue after cold exposure in humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Bioorthogonal Click of Colloidal Gold Nanoparticles to Antibodies In vivo

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation. A Lutetium-177 (177Lu)-based probe linked to the somatostatin analog octreotate ([177Lu]Lu-DOTA-TATE) is approved for the treatment of certain SSTR-expressing tumors and has been shown to improve survival. However, a limiting factor of PRRT is the potential toxicity derived from the high doses needed to kill the tumor. This could be circumvented by combining PRRT with other treatments for an enhanced anti-tumor effect. Photothermal therapy (PTT) relies on nanoparticle-induced hyperthermia for cancer treatment and could be a useful add-on to PRRT. Here, we investigate a strategy combining [177Lu]Lu-DOTA-TATE PRRT and nanoshell (NS)-based PTT for the treatment of SSTR-expressing small-cell lung tumors in mice. Our results showed that the combination treatment improved survival compared to PRRT alone, but only when PTT was performed one day after [177Lu]Lu-DOTA-TATE injection (one of the timepoints examined), showcasing the effect of treatment timing in relation to outcome. Furthermore, the combination treatment was well-tolerated in the mice. This indicates that strategies involving NS-based PTT as an add-on to PRRT could be promising and should be investigated further.

OriginalsprogEngelsk
Artikelnummer1284
TidsskriftPharmaceutics
Vol/bind14
Udgave nummer6
ISSN1999-4923
DOI
StatusUdgivet - 16 jun. 2022

ID: 79046177